REMS-Certified Spravato Care in Omaha
Spravato is not a take-home medication and it is not administered casually. It is available only through a restricted REMS program and must be given in a certified healthcare setting under direct clinical supervision.
At Parker Neuroscience, Spravato treatment is delivered with the same safety-first philosophy that guides the entire practice: defined protocols, appropriate monitoring, diagnostic clarity, and individualized psychiatric care.
Patients begin with a clinical evaluation to determine whether Spravato is appropriate based on their diagnosis, prior treatment history, current medications, medical risk factors, and treatment goals. The purpose of the consultation is not to push every patient toward treatment. It is to determine the safest, most clinically appropriate path forward.
For patients who have tried multiple antidepressants without adequate relief, learn more about treatment-resistant depression care in Omaha.
What Is Spravato?
Spravato is the brand name for esketamine nasal spray. Esketamine is related to ketamine but is administered differently and regulated differently. Unlike IV ketamine therapy, Spravato is FDA-approved for certain adults with treatment-resistant depression.
Spravato is given as a nasal spray in a certified clinical setting. Patients self-administer the medication under direct observation from a healthcare provider, then remain in the clinic for monitoring before discharge.
Because Spravato can cause sedation, dissociation, increased blood pressure, and other effects during or after treatment, monitoring is a required part of care. At Parker Neuroscience, each session is handled with direct RN/APRN oversight and strict discharge criteria.
Who May Be a Candidate for Spravato?
Spravato may be considered for adults with treatment-resistant depression, especially when standard antidepressant treatment has not provided adequate relief.
A patient may be evaluated for Spravato if they have:
- Ongoing depressive symptoms despite previous treatment
- A history of multiple antidepressant trials
- Major depressive disorder that has not responded adequately to standard care
- Difficulty tolerating or responding to traditional medication strategies
- A need for a more structured interventional psychiatry evaluation
Spravato is not appropriate for every patient. Medical history, psychiatric history, blood pressure, substance use history, pregnancy or breastfeeding status, risk of psychosis or mania, and other safety factors may affect candidacy.
Your consultation with Parker Neuroscience is designed to determine whether Spravato is clinically appropriate, whether another treatment may be a better fit, and how treatment would fit into your overall psychiatric care plan.
If medication history, diagnostic clarity, or treatment planning are major concerns, Parker Neuroscience also offers primary care mental health medication support in Omaha.
Spravato vs. IV Ketamine Therapy
Spravato and IV ketamine are related treatment options, but they are not the same.
Spravato is an FDA-approved intranasal esketamine medication for eligible adults with treatment-resistant depression. It is administered under a REMS program in a certified healthcare setting and may be insurance-eligible depending on the patient’s plan and medical necessity.
IV ketamine therapy is administered intravenously and is used off-label in psychiatric care. It may be considered for eligible adults with treatment-resistant depression, PTSD, anxiety, and related psychiatric concerns after clinical evaluation.
The right option depends on your diagnosis, treatment history, safety profile, insurance considerations, and individual goals. Parker Neuroscience can help you understand whether Spravato, IV ketamine therapy, primary care mental health medication support, or another treatment pathway may be the best fit.
Learn more about IV ketamine therapy in Omaha and how it compares with Spravato.
What to Expect During Spravato Treatment
Spravato treatment begins with a clinical evaluation. Dr. Parker reviews your history, prior treatment response, current medications, diagnosis, and safety considerations before determining whether Spravato is appropriate.
If Spravato is recommended, Parker Neuroscience helps guide the clinical and administrative steps involved in care. This may include REMS enrollment, insurance-related documentation, and treatment planning based on medical necessity and eligibility.
During a Spravato session, the medication is administered as a nasal spray under direct clinical observation. After administration, you remain in the clinic for monitoring. Your care team assesses your response, monitors for side effects, and confirms that discharge criteria are met before you leave.
This is structured medical care. The process is deliberate, monitored, and designed around patient safety.
Why Choose Parker Neuroscience for Spravato in Omaha?
Patients looking for Spravato treatment in Omaha are often navigating years of frustration with traditional depression treatment. Parker Neuroscience was built for patients who need a more advanced, medically grounded approach.
REMS-Certified Treatment Environment
Spravato must be administered through the REMS program in a certified healthcare setting. Parker Neuroscience provides Spravato treatment in a controlled clinical environment with defined safety protocols.
Direct RN/APRN Monitoring
Every Spravato session includes direct monitoring by trained clinical staff. Patients are observed throughout the required monitoring period and must meet discharge criteria before leaving.
Interventional Psychiatry Focus
Spravato is not treated as a stand-alone transaction. At Parker Neuroscience, it is part of a larger psychiatric treatment pathway that may include medication review, care coordination, and careful follow-up.
Diagnostic Clarity Before Treatment
Before Spravato is recommended, Dr. Parker evaluates whether the diagnosis, symptom pattern, medication history, and risk factors support treatment. The goal is to understand the whole clinical picture, not simply add another medication.
Private, Patient-Centered Care
Parker Neuroscience provides a private clinical environment designed for safety, calm, and dignity. The experience is not built around volume. It is built around careful care.
Safety and Monitoring During Spravato Treatment
Spravato requires structured monitoring because it can cause effects such as sedation, dissociation, dizziness, nausea, blood pressure changes, and altered perception. These effects are part of why Spravato must be administered in a certified clinical setting rather than taken at home.
At Parker Neuroscience, safety is built into every step of care. Patients are monitored during and after treatment, and discharge is based on defined clinical criteria. If Spravato is not safe or appropriate for you, Parker Neuroscience will tell you directly.
The goal is not just access to treatment. The goal is appropriate treatment, delivered carefully.
Insurance and Access for Spravato
Spravato is FDA-approved and may be insurance-eligible for patients who meet medical necessity and plan requirements. Coverage depends on your insurance plan, diagnosis, prior treatment history, documentation, and authorization criteria.
Parker Neuroscience can help with prior authorization and REMS-related steps when appropriate. During your consultation, the team can discuss what information may be needed, what your plan may require, and whether Spravato appears to be a realistic option for your situation.
Because each insurance plan is different, Parker Neuroscience does not assume coverage before eligibility and benefits are reviewed.
Spravato for Treatment-Resistant Depression
Treatment-resistant depression can feel exhausting. Many patients who reach this point have already tried medication changes, therapy, lifestyle changes, and repeated attempts to feel better. When standard treatment has not provided enough relief, it may be time for a different kind of evaluation.
Spravato is specifically associated with treatment-resistant depression care. For eligible adults, it may offer a different treatment pathway from traditional daily oral antidepressants.
At Parker Neuroscience, Spravato treatment is not approached as a quick fix. It is approached as one possible part of an individualized psychiatric care plan. Dr. Parker evaluates your history, treatment response, symptoms, and safety factors before making any recommendation.
For a deeper overview of symptoms, treatment options, and next steps, visit treatment-resistant depression care in Omaha.
Spravato FAQs
What is Spravato?
Spravato is the brand name for esketamine nasal spray. It is an FDA-approved treatment option for eligible adults with treatment-resistant depression and is administered in a certified healthcare setting under REMS requirements.
Is Spravato the same as ketamine?
No. Spravato is esketamine, which is related to ketamine but is not the same as IV ketamine therapy. Spravato is administered as a nasal spray in a REMS-certified healthcare setting. IV ketamine is administered intravenously and is used off-label in psychiatric care.
Is Spravato FDA-approved?
Yes. Spravato is FDA-approved for treatment-resistant depression in adults, either as monotherapy or in conjunction with an oral antidepressant. It is also approved, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Do I take Spravato at home?
No. Spravato is not dispensed directly to patients for home use. It must be administered in a certified healthcare setting under direct observation, with monitoring after each treatment session.
How long am I monitored after Spravato treatment?
The Spravato REMS program requires patients to be monitored by a healthcare provider for at least two hours after administration. At Parker Neuroscience, patients must meet discharge criteria before leaving.
Is Spravato covered by insurance?
Spravato may be insurance-eligible for patients who meet medical necessity and plan requirements. Coverage depends on your specific insurance plan, diagnosis, prior treatment history, documentation, and authorization criteria.
Who is a candidate for Spravato?
Spravato may be considered for adults with treatment-resistant depression who have not experienced adequate relief from traditional treatment. Candidacy is determined through clinical evaluation, including psychiatric history, medical risk factors, medication history, and safety screening.
Can Spravato help with PTSD or anxiety?
Spravato is FDA-approved for specific depression-related indications, not as a primary treatment for PTSD or anxiety. If you are experiencing PTSD, anxiety, or trauma-related symptoms alongside depression, Dr. Parker can evaluate your full clinical picture and discuss appropriate treatment options.
Start With a Consultation
Ready to talk through your options?
Parker Neuroscience welcomes self-referrals, provider referrals, and general questions from adults exploring advanced psychiatric care in Omaha and throughout Nebraska.
Please do not include medical history, symptoms, medication details, or urgent health concerns in this form.